Patients with either breast cancer, endometrial cancer, or ovarian cancer have started treatment with XMT-1660 in a phase 1 clinical trial.
Dosing of the investigational antibody-drug conjugate (ADC) XMT-1660 has begun in a phase 1 study of patients with breast cancer, endometrial cancer, and ovarian cancer.1
Trial Name: A Phase 1b, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
ClinicalTrials.gov Indentifier: NCT05377996
Sponsor: Mersana Therapeutics
Recruitment Contact: Mersana Therapeutocs 617-715-8214 clinicaltrials@mersana.com
Completion Date: June 2026
XMT-1600 targets B7-H4 and has a precise drug-to-antibody ratio, according to Mersana Therapeutics, Inc. Overexpression of B7-H4 is common in many cancers, including breast, endometrial, and ovarian cancer.1
“The initiation of this phase 1 trial represents an important milestone for Mersana as we continue to build our pipeline across three ADC platforms and seek to further demonstrate the potential of our Dolalock payload and Dolasynthen platform,” said Anna Protopapas, president, and chief executive officer of Mersana Therapeutics. “Based on our promising preclinical data, we believe XMT-1660 has the potential to serve as a highly impactful cancer treatment.
The phase 1b, first-in-human, dose escalation and expansion, multicenter study (NCT05377996) will have a dose-escalation and dose-expansion portion. The co primary end points to be assessed during the dose-escalation phase are the frequency of dose-limiting adverse events (AEs) to determine the recommended phase 2 dose, and the incidence of AEs to determine the safety and tolerability of the agent. The coprimary end point to be evaluated during the dose-expansion phase include safety/tolerability, objective response rate (ORR), and duration of response (DOR).2
Secondary end points explored during the study include ORR, DOR, and time of maximum observed plasma concentration. In addition, the study will assess the area under the concentration-time curve of XMT-1660, systemic clearance of the agent, apparent terminal elimination half-life, volume distribution, trough concentration of XMT-1660, and antibodies and neutralizing antibodies.
To be eligible for the study, patients must have proven recurrent or advanced disease that has progressed after treatment with available anti-cancer therapies. Patients must also have an ECOG performance status of 0 or 1, measurable disease per RECIST v1.1, and be willing to undergo a minimally invasive tumor biopsy for testing.
The study excludes patients who have been previously treated with an ADC containing an auristatin or maytansinoid payload or had major surgery within 28 days of treatment starting in the study. Patients diagnosed with an additional malignancy requiring active treatment, those with current severed, uncontrolled systemic disease, and those with central nervous system metastases are excluded from the study.
Patients with breast, endometrial, or ovarian cancer, including those with fallopian tube or primary peritoneal cavity tumors, are being recruited at sites in New York, Virginia, and Washington.
“We are excited to begin investigating how it may benefit patients in a range of cancers with high unmet needs, said Protopapas, in the press release.1
REFERENCES:
1. Mersana Therapeutics announces initiation of phase 1 trial of XMT-1660 in breast, endometrial and ovarian cancers. News release. Mersana Therapeutics. August 16, 2022. Accessed August 17, 2022. https://bit.ly/3PKi12p
3. A study of XMT-1660 in participants with solid tumors. Clinicaltrials.gov. Updated July 13, 2022. Accessed August 17, 2022.
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
